🍪 CompoundTalk uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsCompounding & FormulationCompounded tirzepatide formulation challenges — 6 month update

Compounded tirzepatide formulation challenges — 6 month update

Dr.Martinez Wed, Mar 19, 2025 at 7:25 AM 11 replies 1,365 viewsPage 1 of 3
This thread is more than 11 months old. Information may be outdated. Consider searching for more recent discussions.
Dr.Martinez
Medical Advisor
3,891
28,456
Nov 2023
Boston, MA
Online
Mar 19, 2025 at 8:50 AM#1

Can someone give me a current state of affairs on compounded tirzepatide as of Q1 2026? It feels like the landscape changes every week.

Last I heard, FDA removed tirzepatide from the shortage list in late 2024 and has been going after compounders. But I'm still seeing some pharmacies advertising it. What's the actual legal status? And what are people paying?

39 19AttorneyGrant, DebRD_ATL, KristenIndy and 36 others
Reply Quote Save Share Report
carl_compliance
Member
234
1,123
Nov 2024
Raleigh, NC
Mar 19, 2025 at 9:07 AM#2

Here's the current status as of March 2026:

Legal status: Complicated. FDA removed tirzepatide from the shortage list in October 2024 and has been issuing warning letters and cease-and-desist orders to compounders. HOWEVER, multiple lawsuits are challenging these enforcement actions, and some pharmacies have obtained temporary restraining orders allowing them to continue compounding.

Availability: Reduced but not eliminated. Several 503B facilities stopped voluntarily. Others are still compounding under legal protection from court orders. Some 503A pharmacies argue they're exempt from the enforcement because they compound on a patient-specific basis.

Pricing (where available):

  • Compounded tirzepatide 10mg vial: $150-275/month
  • Compounded tirzepatide 30mg vial: $300-450 (multi-month supply at lower doses)

Compare to brand Mounjaro/Zepbound at $1,050-1,200/month without insurance.

31 12BrianDallas92, labquiet_amy, emily_PDX and 28 others
Reply Quote Save Share Report
wendy_avl
Member
245
1,123
Oct 2024
Asheville, NC
Mar 19, 2025 at 9:24 AM#3

The key legal case right now is the litigation in the 5th Circuit involving the Outsourcing Facilities Association. The core argument is whether compounded tirzepatide using a different salt form constitutes an "essentially a copy" of branded Mounjaro/Zepbound. If the courts rule it's NOT a copy, compounding could resume broadly.

There's also a constitutional argument about FDA overreach in enforcement. Some pharmacies argue that FDA's administrative determination that the shortage ended is arbitrary and capricious because patients still can't access the medication due to cost.

It's a legal mess. But the practical takeaway: compounded tirzepatide is still available from some pharmacies, just fewer than before.

26 22TomTeleRx, DoseLogDan, SleepFixSam and 23 others
Reply Quote Save Share Report

PeptideMeter — Independent Peptide Analytics

Community-driven peptide testing and vendor rating platform. Transparent results. Unbiased analysis. Trusted by thousands.

View Results
NurseKim_ATL
Senior Member
1,678
7,234
Feb 2024
Atlanta, GA
Mar 19, 2025 at 9:41 AM#4

So if I find a pharmacy still compounding it, am I taking any legal risk as a patient? Can FDA come after me for buying it?

18 17pete_nash, hank_denver, carlos_SATX and 15 others
Reply Quote Save Share Report
emily_PDX
Member
245
1,123
Nov 2024
Portland, OR
Mar 19, 2025 at 9:58 AM#5

No. FDA enforcement actions target pharmacies and prescribers, not patients. You are not breaking any law by filling a valid prescription for a compounded medication. The legal risk sits entirely with the pharmacy and potentially the prescriber.

That said, availability risk is real. If your pharmacy gets shut down mid-treatment, you're back to square one (see the "pharmacy shut down" thread).

20 14PeptideSynthNJ, Dr.KarenChen, Dr.NateNeph and 17 others
Reply Quote Save Share Report

Similar Threads

503A vs 503B compounding — regulatory framework explained4 replies
Compounded semaglutide stability: accelerated degradation study results6 replies
Lyophilized vs liquid peptides — stability and bioavailability comparison18 replies
Bacteriostatic water sourcing and sterility considerations8 replies
State-by-state compounding pharmacy regulations — 2026 map8 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register